News & Press

News & Presskari.sharp@gmail.com2024-04-30T10:42:49-05:00

Press Releases

SkylineDx Announces Commercial Collaboration with Tempus to Advance Patient Care with its Merlin™ Test
Dec 5, 2023

Read More
Multicenter US Study Reveals CP-GEP’s Profound Impact on Stratifying Melanoma Patients for Long-Term Survival
Nov 6, 2023

Read More
Real World Prospective Study shows clinical implementation of Merlin Assay (CP-GEP) in melanoma care
Oct 31, 2023

Read More
Independent study shows favorable long term prognosis for CP-GEP Low Risk melanoma patients
Mar 17, 2023

Read More
SkylineDx announces commercial launch Merlin Assay as CE-IVD kit in Europe
Sep 1, 2022

Read More
SkylineDx announces Medicare coverage for its predictive melanoma assay Merlin^™ Test
May 25, 2022

Read More
SkylineDx presents first prospective validation data Merlin Test at EADO 2022
Apr 21, 2022

Read More
Merlin Test reduces unnecessary surgeries and associated complications for melanoma patients
Feb 24, 2022

Read More
Launch US prospective melanoma trial to validate Merlin Assay
Jun 10, 2021

Read More
Performance Merlin Assay confirmed in independent US validation cohort
Apr 30, 2021

Read More
SkylineDx and Biocartis Sign Collaboration to Develop the Merlin Assay, a Test Predicting Risk for Nodal Metastasis in Melanoma, on Idylla™
Apr 22, 2021

Read More
Dutch consortium investigates biomarker to identify early-stage melanoma at high-risk of recurrence
Feb 15, 2021

Read More
How the Dutch resume elective surgery in melanoma after COVID delays
Aug 26, 2020

Read More
SkylineDx signs 10th collaboration agreement under Falcon Melanoma R&D Program
Jun 23, 2020

Read More
Prognostic model reveals high-risk melanoma patients that need a clinical trial
May 14, 2020

Read More